$CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges$

CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges

Patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) have poor prognosis with a high unmet need for efficacious treatment options. Most patients with r/r large B-cell lymphoma (LBCL) are elderly, which adds to the complexity of choosing the appropriate and effective therapy...

Full description

Saved in:

Bibliographic Details
Main Authors:	Matthew J Frigault, Peter A Riedell, Leyla Shune
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-06-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/6/e009793.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CAR T-Cell Therapy: Paving the Path to a Brighter Future in LBCL
by: Frederick Locke
Published: (2023-03-01)

Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy
by: Jessica S. Little, et al.
Published: (2025-08-01)

CAR T- cell therapy provides an opportunity for further consolidation treatment for relapsed or refractory adult Burkitt lymphoma patients
by: Rui Liu, et al.
Published: (2025-05-01)

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
by: Patrick Born, et al.
Published: (2025-06-01)

Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
by: Yok-Lam Kwong, et al.
Published: (2025-03-01)

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
by: Evgenii Shumilov, et al.
Published: (2025-08-01)

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy
by: Lingling Yin, et al.
Published: (2025-04-01)

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study
by: Alison Sehgal, et al.
Published: (2025-08-01)

Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory/relapsed gliomas
by: Jinshan Gu, et al.
Published: (2025-05-01)

Use of locally produced anti-CD19 CAR-T cells in the treatment of relapsed/refractory B-cell lymphomas in adults
by: N. E. Konoplya, et al.
Published: (2023-09-01)

Early Epcoritamab Administration Revives CAR‐T Cells in Relapsed/Refractory B‐Cell Lymphomas
by: Kensuke Yanashima, et al.
Published: (2025-06-01)

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
by: Sophia Stock, et al.
Published: (2025-01-01)

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
by: Narendranath Epperla, et al.
Published: (2024-11-01)

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
by: Yuhan Yan, et al.
Published: (2024-11-01)

Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma
by: Ning An, et al.
Published: (2025-05-01)

Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review
by: Satchie Sakamoto, et al.
Published: (2024-01-01)

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma
by: Wei Liu, et al.
Published: (2024-04-01)

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia
by: Tingting Yang, et al.
Published: (2025-01-01)

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2024-10-01)

Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
by: Frederick L. Locke, et al.
Published: (2025-06-01)

Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL
by: Gaoxiang Wang, et al.
Published: (2025-03-01)

The Role of Radiotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Post-CAR-T Therapy: A Systematic Literature Review
by: Andrea Emanuele Guerini MD, et al.
Published: (2025-06-01)

Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis
by: Alexander Biederstädt, et al.
Published: (2025-07-01)

Relapsing Polychondritis with Meningoencephalitis Refractory to Immunosuppressant Therapy
by: Mohammad Mousbah Al-Tabbaa, et al.
Published: (2018-01-01)

Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expression
by: Xiaomin Zhang, et al.
Published: (2025-07-01)

CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy
by: Hui Luo, et al.
Published: (2025-05-01)

Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example
by: Gloria Iacoboni, et al.
Published: (2024-12-01)

Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada
by: Jenna Shaw, et al.
Published: (2024-12-01)

Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy
by: Barbara D. Friedes, et al.
Published: (2025-01-01)

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
by: Rossana Di Staso, et al.
Published: (2024-11-01)

Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia
by: Qianyi Zhou, et al.
Published: (2025-03-01)

Breaking Age Barriers: The Benefits of CAR T-Cell Therapies in Treating Large B-Cell Lymphoma in Older Patients
by: Frank Stenner, et al.
Published: (2023-12-01)

Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia
by: Ying Wang, et al.
Published: (2025-02-01)

Case report: CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B-related cirrhosis
by: Danqing Kong, et al.
Published: (2024-12-01)

Incidentally cured psoriasis in a patient with refractory/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report
by: Song-yun Wang, et al.
Published: (2024-10-01)

Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization
by: Phoebe Joy Ho, et al.
Published: (2025-08-01)

Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia
by: Wenyue Cao, et al.
Published: (2025-04-01)

Maximizing the Benefit of CAR T-Cell Therapy in Lymphoma and Multiple Myeloma
by: Federico Simonetta
Published: (2022-10-01)

Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children
by: NA Batmanova, et al.
Published: (2017-07-01)

The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
by: Adrian Schmidt
Published: (2023-10-01)